The applications of pharmacogenomics to neurological disorders

Charles P. Gilman, C. McSweeney, Xiao Yuan Mao

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

The most common neurological disorders, including neurodegenerative diseases and psychiatric disorders, have received recent attention with regards to pharmacogenomics and personalized medicine. Here, we will focus on a neglected neurodegenerative disorder, cerebral ischemic stroke (CIS), and highlight recent advances in two disorders, Parkinson's disease (PD) and Alzheimer's diseases (AD), that possess both similar and distinct mechanisms in regards to potential therapeutic targets. In the first part of this review, we will focus primarily on mechanisms that are somewhat specific to each disorder which are involved in neurodegeneration (i.e., protease pathways, calcium homeostasis, reactive oxygen species regulation, DNA repair mechanisms, neurogenesis regulation, mitochondrial function, etc.). In the second part of this review, we will discuss the applications of the genome-wide technology on pharmacogenomics of mental illnesses including schizophrenia (SCZ), autism spectrum disorders (ASD), attention deficit hyperactivity disorder (ADHD), and obsessive compulsive disorder (OCD).

Original languageEnglish
Pages (from-to)880-890
Number of pages11
JournalCurrent Molecular Medicine
Volume14
Issue number7
Publication statusPublished - 2014
Externally publishedYes

Fingerprint

Pharmacogenetics
Nervous System Diseases
Neurodegenerative Diseases
Neurodegenerative diseases
Precision Medicine
Obsessive-Compulsive Disorder
Neurogenesis
Attention Deficit Disorder with Hyperactivity
DNA Repair
Medicine
Parkinson Disease
Psychiatry
Reactive Oxygen Species
Schizophrenia
Alzheimer Disease
Homeostasis
Repair
Peptide Hydrolases
Genes
Stroke

Keywords

  • Genome wide association study (GWAS)
  • Neurodegenerative diseases
  • Pharmacogenomics
  • Psychiatric disorders

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Molecular Medicine
  • Medicine(all)

Cite this

Gilman, C. P., McSweeney, C., & Mao, X. Y. (2014). The applications of pharmacogenomics to neurological disorders. Current Molecular Medicine, 14(7), 880-890.

The applications of pharmacogenomics to neurological disorders. / Gilman, Charles P.; McSweeney, C.; Mao, Xiao Yuan.

In: Current Molecular Medicine, Vol. 14, No. 7, 2014, p. 880-890.

Research output: Contribution to journalReview article

Gilman, CP, McSweeney, C & Mao, XY 2014, 'The applications of pharmacogenomics to neurological disorders', Current Molecular Medicine, vol. 14, no. 7, pp. 880-890.
Gilman, Charles P. ; McSweeney, C. ; Mao, Xiao Yuan. / The applications of pharmacogenomics to neurological disorders. In: Current Molecular Medicine. 2014 ; Vol. 14, No. 7. pp. 880-890.
@article{7028046ddf9245a8be4ff6fd89e23ff4,
title = "The applications of pharmacogenomics to neurological disorders",
abstract = "The most common neurological disorders, including neurodegenerative diseases and psychiatric disorders, have received recent attention with regards to pharmacogenomics and personalized medicine. Here, we will focus on a neglected neurodegenerative disorder, cerebral ischemic stroke (CIS), and highlight recent advances in two disorders, Parkinson's disease (PD) and Alzheimer's diseases (AD), that possess both similar and distinct mechanisms in regards to potential therapeutic targets. In the first part of this review, we will focus primarily on mechanisms that are somewhat specific to each disorder which are involved in neurodegeneration (i.e., protease pathways, calcium homeostasis, reactive oxygen species regulation, DNA repair mechanisms, neurogenesis regulation, mitochondrial function, etc.). In the second part of this review, we will discuss the applications of the genome-wide technology on pharmacogenomics of mental illnesses including schizophrenia (SCZ), autism spectrum disorders (ASD), attention deficit hyperactivity disorder (ADHD), and obsessive compulsive disorder (OCD).",
keywords = "Genome wide association study (GWAS), Neurodegenerative diseases, Pharmacogenomics, Psychiatric disorders",
author = "Gilman, {Charles P.} and C. McSweeney and Mao, {Xiao Yuan}",
year = "2014",
language = "English",
volume = "14",
pages = "880--890",
journal = "Current Molecular Medicine",
issn = "1566-5240",
publisher = "Bentham Science Publishers",
number = "7",

}

TY - JOUR

T1 - The applications of pharmacogenomics to neurological disorders

AU - Gilman, Charles P.

AU - McSweeney, C.

AU - Mao, Xiao Yuan

PY - 2014

Y1 - 2014

N2 - The most common neurological disorders, including neurodegenerative diseases and psychiatric disorders, have received recent attention with regards to pharmacogenomics and personalized medicine. Here, we will focus on a neglected neurodegenerative disorder, cerebral ischemic stroke (CIS), and highlight recent advances in two disorders, Parkinson's disease (PD) and Alzheimer's diseases (AD), that possess both similar and distinct mechanisms in regards to potential therapeutic targets. In the first part of this review, we will focus primarily on mechanisms that are somewhat specific to each disorder which are involved in neurodegeneration (i.e., protease pathways, calcium homeostasis, reactive oxygen species regulation, DNA repair mechanisms, neurogenesis regulation, mitochondrial function, etc.). In the second part of this review, we will discuss the applications of the genome-wide technology on pharmacogenomics of mental illnesses including schizophrenia (SCZ), autism spectrum disorders (ASD), attention deficit hyperactivity disorder (ADHD), and obsessive compulsive disorder (OCD).

AB - The most common neurological disorders, including neurodegenerative diseases and psychiatric disorders, have received recent attention with regards to pharmacogenomics and personalized medicine. Here, we will focus on a neglected neurodegenerative disorder, cerebral ischemic stroke (CIS), and highlight recent advances in two disorders, Parkinson's disease (PD) and Alzheimer's diseases (AD), that possess both similar and distinct mechanisms in regards to potential therapeutic targets. In the first part of this review, we will focus primarily on mechanisms that are somewhat specific to each disorder which are involved in neurodegeneration (i.e., protease pathways, calcium homeostasis, reactive oxygen species regulation, DNA repair mechanisms, neurogenesis regulation, mitochondrial function, etc.). In the second part of this review, we will discuss the applications of the genome-wide technology on pharmacogenomics of mental illnesses including schizophrenia (SCZ), autism spectrum disorders (ASD), attention deficit hyperactivity disorder (ADHD), and obsessive compulsive disorder (OCD).

KW - Genome wide association study (GWAS)

KW - Neurodegenerative diseases

KW - Pharmacogenomics

KW - Psychiatric disorders

UR - http://www.scopus.com/inward/record.url?scp=84906910117&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906910117&partnerID=8YFLogxK

M3 - Review article

VL - 14

SP - 880

EP - 890

JO - Current Molecular Medicine

JF - Current Molecular Medicine

SN - 1566-5240

IS - 7

ER -